This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound SKIP-PERMANENT HIGH

MDMA

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict SKIP-PERMANENT HIGH

Real clinical signal in PTSD (MAPP1, MAPP2 Phase 3) — but FDA rejected the NDA in 2024, replication trials underway. For a 20yo with no PTSD indication, this is recreational use with measurable cumulative serotonergic neurotoxicity. Cumulative dose tracks with persistent serotonergic damage in primates (Ricaurte 2002 retraction notwithstanding, multiple replication groups have shown SERT density reduction proportional to lifetime dose). HPPD, persistent depression, and "Suicide Tuesday" post-acute crashes are well-documented even at single doses. Verdict SKIP-PERMANENT means: no biohacking case for healthy use. Flips to OPTIONAL only inside a clinical-trial or licensed-clinic PTSD context with a documented indication. Cardiac risk + hyperthermia risk add hard contraindications for combat-sport context where vasoconstrictor + heat-stress loads are already high.

Research pass: stub-manual
Sourcing deep dive

Schedule I in US. Clinical-trial enrollment is the only legal route. Street supply has high adulteration rates (PMA/PMMA, methamphetamine, more recently fentanyl in some markets) — adulteration alone has been the dominant fatality vector in recent years.

Verdict change log
  • 2026-06-05 — Initial verdict SKIP-PERMANENT. Real clinical signal, but for PTSD indication only; cumulative neurotoxicity for chronic use; adulteration risk dominates non-clinical use. (stub)
Open questions / gaps Open
  • Whether the Lykos NDA refiling clears FDA in 2027 cycle.
  • Whether R-MDMA (less neurotoxic enantiomer) ever becomes a legitimate drug — TAK-653 / similar single-enantiomer programs.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…